Pluristem Therapeutics Inc. (PSTI) - 10-Q Summary
Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (a development stage company)
Reporting Period: Six months ended December 31, 2010 (Unaudited)
Business Overview: The Company is a bio-therapeutics firm developing non-personalized cell therapy products derived from human placenta. Its lead product, PLX-PAD, targets peripheral artery disease (PAD). The Company has not generated any revenue since inception and relies on equity financing and government grants to fund operations.
Key Financial Metrics
| Metric (in thousands USD) | Six Months Ended Dec 31, 2010 | Six Months Ended Dec 31, 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,510) | $(3,448) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.22) |
| Cash and Cash Equivalents (Ending) | $4,739 | $1,383 |
| Working Capital | $4,052 | N/A |
| Accumulated Deficit (Inception to Date) | $(44,615) | $(32,652) |
| Cash Used in Operating Activities | $(2,219) | $(1,902) |
| Cash Provided by Financing Activities | $5,008 | $3,577 |
Material Changes vs. Prior Period
- Operating Loss: Net loss increased by approximately 31% to $4.51 million for the six-month period compared to $3.45 million in the prior year period.
- R&D Expenses: Net R&D expenses (after government grants) increased 42% to $2.58 million, driven by increased clinical study activity and the hiring of 8 new employees.
- G&A Expenses: General and administrative expenses rose 22% to $2.00 million, primarily due to a $300,000 increase in stock-based compensation.
- Liquidity: Cash and cash equivalents increased significantly by $3.16 million to $4.74 million, largely due to a private placement offering in October 2010 that generated approximately $5.0 million in net proceeds.
Outlook, Guidance, and Risks
- Capital Resources: Management believes current cash resources, combined with an approved grant from the Israeli Office of the Chief Scientist (OCS) and proceeds from a February 2011 public offering (approx. $38 million), are sufficient to fund operations through the end of 2013.
- Revenue Outlook: The Company does not expect to generate product sales revenue within the next 12 months. Products are not expected to be ready for sale for at least three years.
- Recent Developments:
- Shares began trading on the Tel-Aviv Stock Exchange (TASE) in December 2010.
- Completed a scientific advisory process with the FDA and EMA regarding PLX-PAD clinical development.
- Closed a public offering in February 2011 raising approximately $38 million.
- Risks: Continued operating losses, dependence on equity financing and grants, potential dilution of existing shareholders, and the uncertainty of clinical trial success and regulatory approval.
Investor Verification Checklist
- Cash Burn Rate: Verify the estimated operating cash expenses of $8.0 million for the next 12 months against actual quarterly spending.
- Grant Dependency: Confirm the status and renewal likelihood of the OCS grant, which offsets a significant portion of R&D costs.
- Dilution Impact: Assess the impact of the February 2011 public offering and outstanding warrants/options (approx. 16.8 million total) on future share count and ownership.
- Clinical Milestones: Monitor progress on the Phase II/III study for Critical Limb Ischemia (CLI) and Phase II study for Intermittent Claudication (IC).
- Debt Obligations: Review the balance sheet for any new debt instruments or convertible notes not yet converted to equity.